The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

The Cancer Letter receives investigative, design awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Cancer Letter received five 2020 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists:

  • Art/Photo Illustration, Newsletter/Trade Publications, first place, by Katie Goldberg, for illustrations of the 2019 ASCO annual meeting

  • Editorial Cartooning, Newsletter/Trade Publications, first place, by Katie Goldberg

  • Infographic, Newsletter/Trade Publications, first place, by Jacqueline Ong

  • Art/Photo Illustration, Newsletter/Trade Publications, finalist, by Katie Goldberg, for cover art of 2019

  • Investigative Journalism, Newsletter/Trade Publications, finalist, for “Thirty Days to Death by Cancer,” by Matthew Ong and Paul Goldberg

This is the third consecutive year The Cancer Letter has won first-place design awards, and the first year The Cancer Letter has won awards for cartooning and infographics.

This is also the fourth award Ong has received from SPJDC for his series on cancer-related surgical outcomes, minimally invasive surgery, FDA regulation of devices, and new surgical techniques for the prevention or treatment of cancer.

Here are a few of The Cancer Letter‘s award-winning covers, cartoons, and infographics published in 2019:

story12

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalRegulatory NewsTrials & Tribulations

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
By Edison T. Liu
Sponsored

Why both somatic and germline genomic profiling are essential for precision oncology

Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 
By Heather Hampel and David W. Craig
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account